Bay Area's Tricia Closes $57.5M Series D, Pushes Into Phase III Trial Post author:Sam Post published:November 7, 2017 Post category:BioPharma Proceeds will be used to complete the ongoing pivotal TRCA-301 Phase 3 clinical trial of TRC101. Source: BioSpace You Might Also Like Germany's Novaliq Sets Up U.S. Subsidiary in Cambridge, Massachusetts January 8, 2018 Motif Bio Explodes After Phase III Clinical Trial Success October 3, 2017 Metabolon To Establish Metabolomics Lab In Qatar To Serve Markets In The Middle East May 2, 2017